FDA approval for GSK, Roche drugs could boost balance sheets

09/17/2008 | Reuters

The FDA is set to hand down by Friday its decisions on GlaxoSmithKline's Promacta and Roche Holding's Actemra, a move that may boost the drugmakers' market shares. Citigroup analysts estimated that by 2012, Promacta -- a drug to treat a rare blood disorder -- could generate $509.6 million, while Actemra -- a rheumatoid arthritis medicine -- could bring in $638 million.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Actuary
Meridian Health Plan
Detroit, MI